• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Nephros Inc.

    4/30/25 4:16:33 PM ET
    $NEPH
    Medical/Dental Instruments
    Health Care
    Get the next $NEPH alert in real time by email
    DEFA14A 1 formdefa14a.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

    Filed by the Registrant ☒
    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

      ☐ Preliminary Proxy Statement
      ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
      ☐ Definitive Proxy Statement
      ☒ Definitive Additional Materials
      ☐ Soliciting Material Under Rule 14a-12

     

    NEPHROS, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

      ☒ No fee required.
      ☐ Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.

     

      (1) Title of each class of securities to which transaction applies:
      (2) Aggregate number of securities to which transaction applies:
      (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (Set forth the amount on which the filing fee is calculated and state how it was determined):
      (4) Proposed maximum aggregate value of transaction:
      (5) Total fee paid:

     

      ☐ Fee paid previously with preliminary materials.
      ☐ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

     

      (1) Amount Previously Paid:
      (2) Form, Schedule or Registration Statement No.:
      (3) Filing Party:
      (4) Date Filed:

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $NEPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NEPH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NEPH
    SEC Filings

    See more
    • Nephros Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

      8-K - NEPHROS INC (0001196298) (Filer)

      5/8/25 4:15:47 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEFA14A filed by Nephros Inc.

      DEFA14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:16:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form DEF 14A filed by Nephros Inc.

      DEF 14A - NEPHROS INC (0001196298) (Filer)

      4/30/25 4:15:38 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chief Financial Officer Krandel Judy

      4 - NEPHROS INC (0001196298) (Issuer)

      3/31/25 4:11:30 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Director Amron Arthur H was granted 22,418 shares, increasing direct ownership by 22% to 125,881 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 6:13:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form 4 filed by Director Lask Alisa

      4 - NEPHROS INC (0001196298) (Issuer)

      1/3/25 5:08:03 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Leadership Updates

    Live Leadership Updates

    See more
    • Nephros Hires Judy Krandel as Chief Financial Officer

      SOUTH ORANGE, NJ, Nov. 01, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, announced the appointment of Judy Krandel as Chief Financial Officer (CFO), effective today. In this role, Ms. Krandel will be responsible for directing the company's finances and working closely with the Chief Executive Officer (CEO) and Board of Directors to develop and execute Nephros's long-term strategy. Ms. Krandel joins the company with an impressive track record in financial leadership and strategic planning. She brings more than 20 years of experience in asset management, inv

      11/1/23 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Appoints Joe Harris to Its Board of Directors

      SOUTH ORANGE, NJ, Sept. 08, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration and pathogen detection solutions to the medical and commercial markets, today announced the appointment of Joe Harris to its Board of Directors. "We are excited that Joe is joining our board," said Andy Astor, President and Chief Executive Officer of Nephros. "He brings years of financial, sales, and marketing acumen to the board, with experience in both large and small healthcare ventures." "I am thrilled to join the Nephros board," said Joe Harris. "I believe Nephros is at an exciting point as they continue to focus on sales moment

      9/8/22 4:00:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • RION Appoints Alisa Lask as Chief Commercial Officer

      - Alisa Lask to lead commercialization of the first off-the-shelf exosome therapeutic platform - Two active FDA registrations RION, a biotechnology company headquartered in Rochester, Minnesota pioneering new innovations in exosomes for therapeutic and aesthetic indications, today announced the appointment of Alisa Lask as Chief Commercial Officer. "Alisa brings an exemplary track record gained through both global and U.S. leadership roles at Galderma, Allergan, Zimmer-Biomet, and Eli Lilly and Company, showing significant capability to spearhead commercial strategies to create world-class aesthetic and therapeutic product franchises," said Dr. Atta Behfar, Founder of RION. "She has prov

      1/14/22 9:00:00 AM ET
      $CLGN
      $NEPH
      Industrial Specialties
      Health Care
      Medical/Dental Instruments

    $NEPH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:15:24 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:13:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Nephros Inc.

      SC 13G - NEPHROS INC (0001196298) (Subject)

      2/3/23 3:11:33 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Financials

    Live finance-specific insights

    See more
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended June 30, 2024

      Second-Quarter Net Revenue of $3.3 Million; New Accounts Help Drive Growth in Core Programmatic Business SOUTH ORANGE, NJ, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the second quarter ended June 30, 2024. Financial Highlights* Net revenue of $3.3 million, a decrease of 8% over Q2 prior year; programmatic revenue (excluding emergency response revenue) increased 8% over Q2 prior yearNet loss of $0.3 million, compared to a net loss of $0.4 millionAdjusted EBITDA of ($133,000), compared to ($183,000) *Stated performance

      8/8/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amron Arthur H bought $11,176 worth of shares (5,000 units at $2.24), increasing direct ownership by 5% to 103,463 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/30/24 4:35:22 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Banks Robert R. Jr. bought $112,050 worth of shares (50,000 units at $2.24), increasing direct ownership by 250% to 70,000 units (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      5/16/24 4:49:44 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Amron Arthur H bought $17,130 worth of shares (7,000 units at $2.45) and acquired 91,463 shares (SEC Form 4)

      4 - NEPHROS INC (0001196298) (Issuer)

      3/14/24 4:28:20 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nephros to Participate in the Benchmark Company Annual Discovery One-on-One Investor Conference on December 11, 2024 in NYC

      SOUTH ORANGE, N.J., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced that it will be participating in the Benchmark Company 13th Annual Discovery One-on-One Investor Conference. The event is scheduled for Wednesday, December 11, 2024, at the New York Athletic Club in New York City. Robert Banks, CEO and Judy Krandel, CFO of Nephros, Inc. will be hosting one-on-one and group investor meetings. If you would like to schedule a 1x1 investor meeting please make sure you are registered here: The conference offers emerging growth and dynamic publicly traded comp

      12/4/24 9:00:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Announces Financial Results for Quarter Ended September 30, 2024

      Third-Quarter Net Revenue of $3.5 Million;Operational Improvements Result In First Profitable Quarter SOUTH ORANGE, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions to the medical and commercial markets, today announced financial results for the third quarter ended September 30, 2024. Financial Highlights* Net income of $0.2 million, compared to a net loss of $0.2 millionAdjusted EBITDA of $295,000, compared to $11,000Net revenue of $3.5 million, an 8% increase over Q2 2024; a decrease of 6% over Q3 prior year *Stated performance is relative to same period in the prior year unless otherwise no

      11/7/24 4:01:00 PM ET
      $NEPH
      Medical/Dental Instruments
      Health Care
    • Nephros Schedules Third Quarter 2024 Financial Results Conference Call

      SOUTH ORANGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Nephros, Inc. (NASDAQ:NEPH), a leading water technology company providing filtration solutions for both healthcare and commercial markets, today announced that it will file its third-quarter financial results on Thursday, November 7, 2024 after market close and will host a conference call that same day at 4:30pm ET. Participants may dial into the call as follows:Domestic access: 1 (844) 808-7106International access: 1 (412) 317-5285 Upon joining, please ask to be joined into the Nephros conference call. An audio archive of the call will be available shortly after the call on the Nephros Investor Relations page. Alternatively, a repl

      10/31/24 7:30:00 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care

    $NEPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • B. Riley FBR initiated coverage on Nephros with a new price target

      B. Riley FBR initiated coverage of Nephros with a rating of Buy and set a new price target of $12.50

      1/26/21 6:12:57 AM ET
      $NEPH
      Medical/Dental Instruments
      Health Care